575 related articles for article (PubMed ID: 18348593)
21. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
[TBL] [Abstract][Full Text] [Related]
23. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
[TBL] [Abstract][Full Text] [Related]
24. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
25. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Cohen D; Correll CU
J Clin Psychiatry; 2009 May; 70(5):765-6. PubMed ID: 19552870
[No Abstract] [Full Text] [Related]
26. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
27. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
28. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
29. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
30. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll CU; Frederickson AM; Kane JM; Manu P
Schizophr Res; 2007 Jan; 89(1-3):91-100. PubMed ID: 17070017
[TBL] [Abstract][Full Text] [Related]
31. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Shajahan P; Keith S; Majjiga C; Murphy J; MacRae A; Bashir M; Taylor M
J Clin Psychiatry; 2009 May; 70(5):692-8. PubMed ID: 19284930
[TBL] [Abstract][Full Text] [Related]
32. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
33. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
[TBL] [Abstract][Full Text] [Related]
35. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
[TBL] [Abstract][Full Text] [Related]
36. Neutropenia associated with quetiapine, olanzapine, and aripiprazole.
Lander M; Bastiampillai T
Aust N Z J Psychiatry; 2011 Jan; 45(1):89. PubMed ID: 21058927
[No Abstract] [Full Text] [Related]
37. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
38. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
McDougle CJ; Stigler KA; Erickson CA; Posey DJ
J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
[TBL] [Abstract][Full Text] [Related]
39. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Dubois D
Curr Opin Pediatr; 2005 Apr; 17(2):227-33. PubMed ID: 15800418
[TBL] [Abstract][Full Text] [Related]
40. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.
Feng S; Melkersson K
Neuro Endocrinol Lett; 2012; 33(5):493-8. PubMed ID: 23090266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]